Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study ivps42020-09-18T09:35:13-04:00 Read More
Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study ivps42020-09-17T15:12:35-04:00 Read More
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) Virtual Conference ivps42020-09-09T22:59:54-04:00 Read More
Achieve Life Sciences to Present at Upcoming Investor Conferences ivps42020-09-02T13:02:07-04:00 Read More
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program ivps42020-08-06T15:11:37-04:00 Read More
